Combination therapy of Eribulin with Trastuzumab for HER2 positive metastatic breast cancer.
Phase 2
- Conditions
- HER2 positive metastatic breast cancer
- Registration Number
- JPRN-UMIN000009296
- Lead Sponsor
- Setouchi Breast Project
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Simultaneous or metachronous (within 5 years) double cancers. 2.Pregnant or breast-feeding women. 3. Psychiatric diseases. 4. Systemic and continuous steroid treatment. 5. with symptomatic brain metastasis 6. Uncontrolled hypertension. 7. Uncontrolled diabetes mellitus or the disease being treated by continuous insulin administration.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Progression free survival, Overall survival, Safety